Eptinezumab Trial for Migraine Relief

This study is testing a medicine called eptinezumab to see if it helps people with migraines, especially those who haven't felt better using other anti-CGRP medicines. Anti-CGRP medications target a peptide (a small protein) linked to causing migraines. This trial is for people who have at least 8 migraine days a month and haven't responded well to other migraine treatments like monoclonal antibodies (mAb) or gepants.

Participants shouldn't have used certain migraine medicines too much before joining. It's also not for those who have tried more than one CGRP medicine without success or have had certain cancers in the past five years. Importantly, you can't join if you've tried eptinezumab before.

• Trial Length: The study includes a screening visit and a baseline period.
• Visits: Regular visits are needed to monitor health and response to treatment.
• Risks: Possible side effects and exclusion for certain health conditions.